Novo Nordisk Earnings Call: Growth Engine Meets 2026 Reset

Novo Nordisk ((NVO)) has held its Q4 earnings call. Read on for the main highlights of the call.

Novo Nordisk’s latest earnings call struck a cautious but resolutely optimistic tone. Management highlighted powerful structural tailwinds in obesity and GLP‑1 treatments, strong cash generation and a robust innovation pipeline, yet tempered this with unusually weak guidance for 2026, driven by pricing pressure, policy shifts and margin headwinds. Investors are left balancing a visibly challenged near-term earnings path against a company that remains firmly on the front foot in one of the fastest‑growing segments in global healthcare.

Solid 2025 topline growth but softer profit expansion

Sales rose 10% in 2025, with operating profit up around 6% at constant exchange rates, underlining that the core business is still expanding despite mounting headwinds. Currency movements weighed on reported figures, leaving operating profit down 1% in Danish kroner, but the underlying performance remained positive. Net profit reached DKK 102 billion and cash from operations came in close to DKK 120 billion, giving Novo Nordisk ample financial firepower even as it prepares investors for a more difficult 2026.

Obesity franchise and Wegovy continue to power growth

The obesity business was the standout growth engine, with obesity care sales jumping 31% in 2025. Wegovy sales surged 134% year-on-year to DKK 28 billion, underscoring the scale of demand. The Wegovy pill, approved in late December and launched in the U.S. on 5 January, showed brisk early uptake: roughly 50,000 prescriptions in the week ending 23 January, mostly self-pay, and later updates showed more than 170,000 people already on the oral product. Combined weekly new-to-brand prescriptions for Wegovy pill and injection now exceed about 75,000, while the injectable alone reached roughly 230,000 total weekly prescriptions around the holiday period, reinforcing Wegovy’s central role in the obesity category.

GLP‑1 leadership underpins global growth

Novo Nordisk’s dominance in GLP‑1 therapies remains a key strategic asset. The global GLP‑1 market expanded more than 30% in 2025, and Novo Nordisk increased sales 8% in the U.S. and 14% in International Operations. In those international markets, GLP‑1 volume grew an impressive 44%, with the company commanding about 62% volume market share. This entrenched position in a rapidly expanding therapeutic class supports management’s confidence in long-term growth, even as pricing and policy headwinds intensify.

Self-pay and direct channels emerge as powerful growth levers

The company reported particularly strong momentum in self-pay and direct-to-consumer channels, especially for obesity medicines. Around 30% of injectable Wegovy prescriptions are now self-pay, and the NovoCare Pharmacy platform introduced in March 2025 is helping capture additional demand. Across Wegovy and Ozempic, self-pay prescriptions have climbed to nearly 120,000 weekly total prescriptions, signaling a structurally different demand profile less reliant on traditional reimbursement. Early coverage for the Wegovy pill from major pharmacy benefit managers and insurers is also helping to broaden access, albeit within a complex, shifting U.S. pricing environment.

Pipeline progress: CagriSema and zenagamtide impress

R&D data releases were a bright spot on the call. In the REIMAGINE 2 trial, the dual-agonist CagriSema 2.4 mg delivered superior A1c reductions versus semaglutide 2.4 mg (1.91 vs. 1.76 percentage points from a baseline around 8.2%) and stronger weight loss, with a mean 14.2% reduction. Notably, more than 40% of participants lost over 15% of body weight and about 25% lost more than 20%, results that, if replicated commercially, could further differentiate Novo Nordisk’s obesity portfolio. Zenagamtide also showed promise in Phase II, with once-weekly injections reducing A1c by up to 1.8 percentage points (baseline 7.8%) and the oral version showing reductions up to 1.5 percentage points. High proportions of patients reached HbA1c below 7% (up to 89.1% weekly and roughly 78% oral), pointing to a potentially important new diabetes and metabolic asset.

Broad pipeline and packed 2026 catalyst calendar

Beyond individual assets, Novo Nordisk stressed the breadth and depth of its pipeline. Key upcoming events in 2026 include the REIMAGINE 1 readout in the first quarter and REDEFINE 4, which will compare weight loss versus tirzepatide, also expected in the first quarter. The etavopivat HIBISCUS Phase III trial in sickle cell disease is slated for a second-quarter readout. Regulatory decisions are anticipated in the second half of 2026 for denecimig and various semaglutide filings, while Phase III AMBITION and AMAZE programs for zenagamtide are planned to start during the year. This sequence of readouts and filings could provide multiple value inflection points even as reported financials face pressure.

Capital allocation: heavy investment and continued shareholder payouts

Novo Nordisk continued to spend aggressively to secure long-term capacity and innovation, allocating about DKK 60 billion to manufacturing expansion and around DKK 30 billion to R&D and business development in 2025. At the same time, it maintained its commitment to capital returns: approximately DKK 52 billion was returned to shareholders, and a final dividend proposal brings the total 2025 dividend to DKK 11.70 per share, a 2.6% increase. A new share repurchase program of up to DKK 15 billion was also announced, signaling management’s confidence in the company’s long-term earnings power despite the near-term reset.

Cash flow resilience and evolving balance sheet profile

The company offered clearer definitions and outlook for cash flows, guiding 2026 free cash flow to DKK 35–45 billion and capital expenditures at about DKK 55 billion. While this implies significant cash outflows in the near term, management expects capex to decline in subsequent years as current manufacturing projects are completed. The guidance suggests Novo Nordisk will remain comfortably cash generative, even as it funds aggressive capacity expansion and absorbs a tougher pricing backdrop.

Manufacturing build-out supports supply confidence

Supply constraints have been a persistent concern in the GLP‑1 and obesity markets, but management reiterated confidence in meeting Wegovy pill demand in the U.S. despite strong early uptake. Key active pharmaceutical ingredient (API) facilities and capacity expansion projects are said to be on track, with major API sites expected to come online during the year. This supply visibility is crucial, as any disruption could undermine the growth narrative just as competition intensifies.

2026 guidance flags a sharp near-term earnings reset

The most striking element of the call was the guidance for 2026, which points to a notable short-term contraction. Adjusted sales growth is expected between minus 5% and minus 13% at constant exchange rates, with adjusted operating profit forecast in the same negative range. Given current foreign exchange assumptions, reported sales growth in Danish kroner is expected to be roughly 3 percentage points lower than the CER numbers, and reported operating profit growth about 5 percentage points lower. Management attributed this downturn primarily to pricing headwinds, impacts from new policy and pricing frameworks, and loss of exclusivity in some markets, with U.S. sales in particular expected to decline by double digits.

Pricing and policy headwinds weigh heavily, especially in the U.S.

A central theme of the call was mounting pressure from pricing and policy changes, particularly in the United States. Lower realized prices are being driven by increased investments in market access, shifts in channel mix between cash-pay and reimbursed volumes, and the effect of agreements tied to policy measures including most-favored-nation-type mechanisms. Management expects these dynamics to result in a significant double-digit sales decline in the U.S. in 2026, even as underlying volume demand remains strong. This creates a challenging near-term backdrop for investors, who must weigh strong structural growth against a temporary but material price reset.

Margin compression and exceptional costs cloud the profit picture

Profitability came under pressure in 2025 as gross margin slipped to 81% from 84.7% in 2024. The decline was driven mainly by amortization and depreciation linked to the acquisition and restructuring of Catalent manufacturing sites. On top of that, company-wide restructuring costs of about DKK 8 billion dragged on operating profit. Management emphasized that, excluding such exceptional items, underlying operating profit growth would have been stronger, but also acknowledged that the business is transitioning into a period of lower margins as it invests heavily and absorbs lower prices in its largest market.

Market access setbacks and shifting payer landscape

The company is grappling with an uneven payer environment in the U.S. Several states reduced Medicaid coverage for anti-obesity medicines at the start of 2026, contributing to a drop in injectable Wegovy prescriptions in the early part of the year. While Medicare Part D coverage is expected to ramp up over time, Novo Nordisk anticipates only a modest impact in 2026, with a more meaningful benefit not expected until 2027. This highlights the complexity of translating strong clinical and consumer demand into stable, reimbursed revenue streams.

Loss of exclusivity and competitive risks in international markets

Outside the U.S., the company faces growing uncertainty from generic competition. The loss of exclusivity for semaglutide in markets such as Canada, alongside broader competitive intensity, is expected to be a low single-digit drag on group sales. Management noted that the timing and scale of generic launches, especially in Canada, remain uncertain and could alter outcomes. Nonetheless, the company signaled that while these headwinds are manageable, they are another factor dampening the near-term growth outlook for International Operations.

Lower margins on Wegovy pill create a mix challenge

While the Wegovy pill is a major strategic launch, its economics differ from the injectable form. Management confirmed that the oral version carries a lower gross margin, though it is still described as attractive. As the volume mix shifts toward oral formulations, this will likely exert some downward pressure on overall margins. For investors, the pill represents both a substantial growth opportunity and an incremental headwind for profitability metrics as it scales.

High capital intensity sustains near-term cash pressures

The company’s elevated investment cycle is set to continue in 2026, with capital expenditure guided at about DKK 55 billion. Much of this is directed to manufacturing capacity to support obesity and GLP‑1 demand. While management expects capex to moderate in later years as projects complete, the current spend level represents a significant drag on free cash flow and underscores that Novo Nordisk is still in the build-out phase of a much larger global obesity franchise.

Wide guidance range reflects earnings volatility and uncertainty

The unusually wide guidance range for 2026 (minus 5% to minus 13% for both sales and operating profit at constant exchange rates) underscores the high degree of uncertainty management sees in the near term. The company cited volatile price-volume dynamics and the rapidly evolving self-pay obesity market as key unknowns that could swing results materially in either direction. This reinforces the message that, while the structural growth story remains intact, reported earnings could be bumpy as the business digests policy shifts, pricing resets and changing payer behavior.

Guidance and outlook: short-term pain for long-term gain

Looking ahead, Novo Nordisk’s formal guidance points clearly to a transitional year in 2026. Adjusted sales and operating profit are both expected to decline between 5% and 13% at constant exchange rates, with reported figures further depressed by currency effects. The outlook assumes continued global expansion of the GLP‑1 market but offsets this with lower realized prices, MFN-related impacts and loss of exclusivity in certain markets, alongside a sizable U.S. sales decline driven by lower prices and channel mix. Even so, the company expects free cash flow of DKK 35–45 billion, capex of about DKK 55 billion, and cash returns to shareholders exceeding DKK 60 billion, including a new share buyback program of up to DKK 15 billion. This mix of declining earnings and robust capital returns encapsulates management’s view that 2026 is a reset year within a much larger long-term growth trajectory.

Novo Nordisk’s earnings call painted a nuanced picture: operationally, the company is executing well, extending its lead in obesity and GLP‑1 markets, expanding its self-pay and direct channels, and advancing a pipeline that could sustain growth for years. Financially, however, investors must brace for a period of falling reported sales and profits in 2026, driven by pricing, policy and investment headwinds. For long-term holders, the story remains anchored in structural demand for obesity treatments and a broadening metabolic portfolio; for shorter-term investors, the focus will be on how quickly the company can move beyond this earnings air pocket and convert its scientific and commercial momentum back into visible profit growth.